Rethinking the appraisal and approval of drugs for type 2 diabetes

Naci, HuseyinORCID logo; Lehman, Richard; Wouters, Olivier J.ORCID logo; Goldacre, Ben; and Yudkin, John S (2015) Rethinking the appraisal and approval of drugs for type 2 diabetes BMJ, 351 (h5260). ISSN 1756-1833
Copy

The process for approving new drugs for type 2 diabetes illustrates the significant shortcomings of the regulatory standards for licensing, reimbursing, and adopting new drugs. Regulatory reform is needed to improve the real-world therapeutic value of anti-diabetic drugs.
Item Type Article
Departments LSE Health
DOI 10.1136/bmj.h5260
Date Deposited 22 Oct 2015 14:03
URI https://researchonline.lse.ac.uk/id/eprint/64115

Explore Further

picture_as_pdf
subject
Accepted Version
Download

Atom BibTeX OpenURL ContextObject in Span OpenURL ContextObject Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation METS MODS RIOXX2 XML Reference Manager Refer ASCII Citation
Export

Downloads